Apomorphine - Takeda

Drug Profile

Apomorphine - Takeda

Alternative Names: Ixense; Spontane; TAK 251; Uprima

Latest Information Update: 07 Feb 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pentech Pharmaceuticals
  • Developer Pentech Pharmaceuticals; Takeda
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Erectile dysfunction
  • Discontinued Neurogenic bladder

Most Recent Events

  • 07 Feb 2013 Discontinued - Phase-I for Erectile dysfunction in Japan (Sublingual)
  • 02 Feb 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 14 Aug 2006 No development reported - Phase-I for Erectile dysfunction in Japan (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top